METRICSTREAM, INC.

Data from the pivotal GEOMETRY mono-1 Phase II study published today in The New England Journal of Medicine (NEJM) show treatment with Tabrecta™...

Novartis today announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine. These results show...

Sandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes...

Novartis will highlight the strength of its oncology research programs at the upcoming 52nd Annual Meeting of the American Society of Clinical...

Final analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic...

Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist...

Novartis today announced new data for multiple investigational and established non-small cell lung cancer (NSCLC) treatments, including results...

Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)*
Sandoz plans to complete Phase III...

Overall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanomaNew...

New oral suspension formulation, designed for younger children with rare blood disorder, is now approved
For about one in four children...